Grants for Native American tribal organizations - Health

The "Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences" grant aims to fund educational activities that inspire individuals from diverse and underrepresented backgrounds to pursue careers or further studies in biomedical and behavioral sciences research.

Funding Opportunity PurposeThe full-scale Diversity Centers for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. The MSIs must have a mission to serve historically underrepresented populations in biomedical research that award doctorate degrees in the health professions or the sciences related to health, and have received an average of less than $50 million per year in NIH support and less than $25 million per year of R01 total cost of NIH support for the past three fiscal years. The purpose of this FOA is to call for applications for UG3/UH3 cooperative agreements to support the development and planning for a multi-investigator, interdisciplinary team to develop administrative, genomic workforce development and community engagement cores and 2-3 interrelated, innovative genomic research projects that address one or more critical issues in genomics including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics, ethical, legal, and social implications of genomic research (ELSI); and/or genomics and health equity. The outcome of the development and feasibility studies will be fully developed plans to carry out all activities of a full-scale Diversity Center for Genome Research. Along with its scientific goals, the DCGR should expand the pool of diverse genomic scientists, clinician scientists, and researchers who can perform innovative genomics research by providing didactic, practicum and research activities and experiences that are aligned with the research projects.

This funding opportunity supports innovative research projects that aim to improve health outcomes and promote health equity in the U.S. by addressing social determinants of health and enhancing healthcare delivery systems.

This funding opportunity supports researchers in analyzing existing data from a major study on adolescent brain development and health to uncover new insights and address health disparities among youth.

This funding opportunity supports the development of innovative tools and methodologies to study the human virome, inviting a diverse range of organizations to enhance our understanding of how viruses impact human health and disease.

The "Neuropathological Interactions Between COVID-19 and ADRD" grant aims to fund research that investigates how COVID-19 affects the brain and cognitive outcomes in models with Alzheimer's Disease and related dementias (AD/ADRD), how it accelerates these conditions in early stages, and how it potentially increases the risk for future AD/ADRD.

This funding opportunity provides financial support to state and tribal governments to improve mental health services for children and youth with serious emotional disturbances and their families.

This funding provides up to $3.3 billion to cities, counties, and tribal entities in California to develop and improve facilities that expand behavioral health treatment and services for Medi-Cal beneficiaries.

This funding opportunity provides financial support for the creation of significant scholarly works in biomedicine and health, aimed at researchers, public health officials, and scholars in the U.S. who are addressing critical gaps in these fields.

The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qualification program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phasethe project must have a set of operational milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years.The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD. Achieving this goal will greatly facilitate the development of treatments for SUDs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

This funding opportunity supports research institutions and organizations in developing innovative technologies to study how neural cell groups in rodents respond to addictive substances, aiming to deepen our understanding of addiction-related behaviors.

This funding opportunity provides financial support to state and local governments, community organizations, and other eligible entities to improve access to long-term services and supports by enhancing their No Wrong Door systems through collaboration and modernization efforts.

This funding opportunity supports innovative research on new screening methods and treatments for severe conditions detectable in newborns, aimed at improving early detection and health outcomes.

This grant provides funding for institutional research training programs to develop skilled neuroscientists through comprehensive training in research, statistics, and communication, specifically targeting advanced graduate students and postdoctoral fellows.

This funding opportunity supports researchers in developing innovative theories and methods to better understand the complex interactions of genetic and non-genetic factors influencing human traits, particularly in relation to health and cancer risk.

The grant titled "Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Data Coordinating Center (Collaborative U24 Trial Required)" is aimed at funding the development and implementation of a Data Coordinating Center to manage data, provide statistical support, and ensure overall coordination for a multi-site clinical trial focused on preventing cardiovascular disease in young adults at high risk, while also promoting community engagement, diversity, and health equity.

The "Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults" grant aims to fund a network of clinical trials that will study the safety and potential effectiveness of psychedelic drugs in treating chronic pain in older adults, with a focus on those aged 75 and above.

The purpose of this program is to assist in addressing the opioid overdose crisis in Tribal communities by increasing access to FDA-approved medications for the treatment of opioid use disorder (MOUD), and supporting the continuum of prevention, harm reduction, treatment, and recovery support services for opioid use disorder (OUD) and co-occurring substance use disorders.

This funding opportunity supports innovative research teams using non-human animal models to develop advanced methods for measuring and analyzing behavior in relation to environmental factors.

HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance. The goal of this initiative is to support research aimed at (1) identification of targets and pathways by which transcriptional activity of HIV can be suppressed in HIV reservoirs including the CNS in people with SUD, and (2) application of emerging small molecule drug discovery approaches to identify novel compounds that can be utilized as pharmacological probes and as drugs to suppress HIV transcription in people with HIV-SUD comorbidity.